Drugs / FD-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06731699 | Mar 2024 → Jan 2026 overdue | acute myeloid leukemia, non-Hodgkin lymphoma | Chengdu FenDi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07088133 | Aug 2025 → Jul 2026 overdue | hepatitis B virus infection, hepatocellular carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06731699 ↗ |
| Modality | Vaccine | “therapeutic hepatitis B vaccine FD-001” NCT07088133 ↗ |
| Route | Oral | “oral administration occurred on day one” NCT06731699 ↗ |